Dogwood Therapeutics, Inc.
DWTXAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | May 19, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 27, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 20, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 30, 2026 |
| HC Wainwright & Co. | maintain | Buy | Sep 30, 2025 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | Apr 23, 2025 |
Earnings History
Next report: Mar 17, 2027 · EPS est. $-0.16| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.14 | $-0.15 | $100.0K | $100.0K |
| Aug 13, 2026 | $-0.34 | $-0.14 | — | — |
| May 14, 2026 | $-0.15 | $-0.22 | — | — |
| Mar 18, 2026 | $-0.26 | $-0.86 | — | — |
| Nov 6, 2025 | $-8.20 | $-1.23 | — | — |
| Aug 13, 2025 | $-1.99 | $-1.26 | — | — |
| May 8, 2025 | $-8.45 | $-0.77 | — | — |
| Feb 26, 2025 | $-5.90 | $-1.36 | — | — |
News
- Completed the Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy, top-line results to be announced in November 2026 -
ATLANTA, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that management will participate in the upcoming 2026 Maxim Growth Summit, taking place from October 12-14, 2026, in New York, NY. The conference brings together industry leaders, innovators, and investors to explore the latest trends and advancements across several industr…
- Enrollment of 239 Patients Meets Upper End of Planned Enrollment Target Range - - Topline Data Expected in November 2026 - ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced the completion of patient enrollment in its ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathic Pain (“CINP”) trial.
Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript
Dogwood Therapeutics NASDAQ: DWTX said its Phase 2b study of Halneuron, an investigational treatment for chemotherapy-induced neuropathic pain, has enrolled more than 230 patients and is expected to report top-line data later this fall.
ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (exp…
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled –